When considering the findings of these studies and the potential of future research, physicians should be well-informed of the G6PD status of their COVID-19 infected patients, using remdesivir or other antiviral medication with great caution in positive patients, particularly those within class I [77]. This evidence concerns the gene G6PD and COVID-19.